Exploring the Potential for JAK1 Selectivity in Autoimmune Dermatological Conditions

Time: 1:15 pm
day: Day One


  • Overcoming pre-clinical hurdles in dermatology to enable topical JAK inhibitor development
  • Considering route of delivery and the implications on safety and efficacy
  • Preparing a JAK inhibitor pipeline for transition from pre-clinic to phase 1 trials